Trial Profile
A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Apr 2021 Status changed from active, no longer recruiting to completed.
- 24 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2020.
- 24 Oct 2019 Planned primary completion date changed from 1 Dec 2018 to 15 Nov 2019.